Print Clear form

MASSACHUSETTS

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) SUPPLEMENTAL FORM

Submit this form with the *rTMS Form*, which can be found on the following page and on the Mass Collaborative website.

FOR THESE MEMBERS:	FAX YOUR REQUEST TO:
Blue Cross Blue Shield of Massachusetts employees and dependents (for privacy reasons)	**1-888-608-3693**
All other requests	**1-888-641-5199**

PLEASE TELL US:	
Are you willing to accept the network rate while treating this member?	❒ Yes ❒ No
Would you like us to contact you through your secure PHI fax line?	☐ Yes ❒ No
Requesting provider's fax number:	
Service provider's address: Street:	
City, State, Zip code:	

CLEAR FORM

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION REQUEST FORM

☐ In Network		☐ Out of Network	
MEMBER NAME:		DOB:	GENDER:
HEALTH PLAN:	FAX #:	POLICY #:	
Date and Time of Request:			
Treating Clinician/Facility:			
If the treating clinician is not making this request, has the treating clinician been notified? ☐ Yes ☐ No			
Phone #:		NPI:	TIN:
Servicing Clinician/Facility:			
Phone #:		NPI:	TIN:

INITIAL TREATMENT

1. Has a confirmed diagnosis of severe major depressive disorder (MDD) single or recurrent episode

☐ F32.2	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, SEVERE (WITHOUT PSYCHOTIC FEATURES)
☐ F33.2	MAJOR DEPRESSIVE DISORDER, RECURRENT EPISODE, SEVERE (WITHOUT PSYCHOTIC FEATURES)

Pre-treatment rating scale: GDS _____, PHQ-9 _____, BDI _____, HAM-D _____, MADRS _____, QIDS _____, or IDS-SR _____

AND

2. One or more of the following:

☐ Resistance to treatment with psychopharmacologic agents as evidenced by a lack of a clinically significant response to **four adequate trials of at least six weeks duration** of psychopharmacologic agents in the current depressive episode from at least two different agent classes as documented by standardized rating scales that reliably measure depressive symptoms (GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS, or IDS-SR); or

☐ Inability to tolerate psychopharmacologic agents as evidenced by **four trials** of psychopharmacologic agents from at least **two different agent classes (at least one of which is in the antidepressant class)**, with distinct side effects; or

☐ History of response to rTMS in a previous depressive episode; or

☐ Currently receiving electroconvulsive therapy (ECT)

☐ Currently considering ECT; rTMS may be considered as a less invasive treatment option

**Note for reference:* *Remission is typically defined by the following measurement scores: Beck Depression Scale (BDI) score of <9, Hamilton Depression Rating Scale (HAM-D) score of <8 on the HAM-D-17 and <11 on the HAM-D-24, Montgomery-Asberg Depression Rating Scale (MADRS) score of < 10, Patient Health Questionnaire (PHQ-9) score of < 5*

AND

☐ **3. A trial of an *evidence-based psychotherapy* known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms (GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR).**

AND

☐ **4. An order written by a psychiatrist (MD or DO) who has examined the patient and reviewed the record. The physician will have experience in administering TMS therapy. The treatment shall be given under direct supervision of this physician.**

Potential Contraindications (please select all applicable contraindications the patient has from the list below):

☐ Seizure disorder or any history of seizures (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence)

☐ Presence of acute or chronic psychotic symptoms or disorders in the current depressive episode

☐ Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system

☐ Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 cm from the TMS magnetic coil or other implanted metal items including but not limited to a cochlear implant, implanted cardiac defibrillator (ICD), pacemaker, vagus nerve stimulation (VNS), or metal aneurysm clips or coils, staples, or stents.

Note: *Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS.*

☐ Prior failed trial of an adequate course of treatment with ECT or vagus nerve stimulation (VNS) for Major Depressive Disorder

The patient is currently: ☐ pregnant or ☐ nursing

☐ The patient has a current suicide plan or recent suicide attempt

Current active history of (check those that apply):

☐ Eating Disorder

☐ Psychotic Disorder, including Schizoaffective Disorder

☐ Bipolar Disorder

History of (check those that apply):

☐ Substance Use Disorder

☐ Obsessive Compulsive Disorder

☐ Post-Traumatic Stress Disorder

RETREATMENT

☐ **1. Patient met the guidelines for initial treatment AND meets guidelines currently.**

AND

☐ **2. Subsequently developed relapse of depressive symptoms**

AND

☐ **3. Responded to prior treatments as evidenced by a greater than 50% improvement in standard rating scale measurements for depressive symptoms (e.g., GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR scores).**

Post-treatment rating scale: GDS _____, PHQ-9 _____, BDI _____, HAM-D _____, MADRS _____, QIDS _____, or IDS-SR _____

Dates of initial treatment, if known:

TREATMENT TYPE(S) REQUESTED

FDA-approved TMS device to be used for the following treatment:		**Number of Sessions:**
☐ 90867	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — INITIAL, INCLUDING CORTICAL MAPPING, MOTOR THRESHOLD DETERMINATION, AND DELIVERY AND MANAGEMENT	
☐ 90868	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — SUBSEQUENT DELIVERY AND MANAGEMENT, PER SESSION	
☐ 90869	THERAPEUTIC REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (TMS) TREATMENT — SUBSEQUENT MOTOR THRESHOLD REDETERMINATION WITH DELIVERY AND MANAGEMENT	